Dosimetry for treatment with radiolabelled somatostatin analogues. A review

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 1, 2010, Pages 37-51

  Cremonesi, M ^a   Botta, F ^a   Di Dia, A ^a   Ferrari, M ^a   Bodei, L ^a   De Cicco, C ^a   Rossi, A ^a   Bartolomei, M ^b   Mei, R ^a   Severi, S ^c   Salvatori, M ^d   Pedroli, G ^a   Paganelli, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b BUFALINI HOSPITAL   (Italy)

^c Scientific Institute for the Study and Treatment of Tumors   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Drug toxicity; Neuroendocrine tumors; Radioisotopes

Indexed keywords

DOTATATE IN 111; DOTATATE LU 177; DOTATATE Y 90; DOTATOC GA 68; DOTATOC IN 111; DOTATOC Y 86; DOTATOC Y 90; GALLIUM 68; INDIUM 111; LUTETIUM 177; PENTETREOTIDE IN 111; PEPTIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; YTTRIUM 86; YTTRIUM 90;

CORRELATIONAL STUDY; DOSIMETRY; INFORMATION; ISOTOPE LABELING; KINETICS; MEDICAL LITERATURE; MODEL; MULTIPLE CYCLE TREATMENT; ORGAN; OUTCOME ASSESSMENT; PROTECTION; RADIOBIOLOGY; REVIEW;

HUMANS; ISOTOPE LABELING; MODELS, BIOLOGICAL; RADIOMETRY; RADIOTHERAPY; SOMATOSTATIN;

EID: 77952476135     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Lambert B, Cybulla M, Weiner SM, Van De Wiele C, Ham H, Dierckx RA et al. Renal toxicity after radionuclide therapy. Radiat Res 2004; 161:607-611
2. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004; 31:1038-1046
3. Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA et al. Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest 2009;32:360-369
4. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009;5:382-393
5. Loevinger R, Budinger T, Watson EE. MIRD Primer for absorbed dose calculations. New York, NY: The Society of Nuclear Medicine; 1991.
6. Stabin M, Siegel J, Lipsztein J, Hunt J, Brill A, Sparks R et al. RADAR (Radiation Dose Assessment Resource) [Homepage]. [cited 2010 January 26]. Available at: www.doseinfo-radar.com (mirror: doseinfo-radar.aifm.it).
7. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-1027
8. Stabin MG. Uncertainties in internal dose calculations for radiopharmaceuticals. J Nucl Med 2008;49:853-860
9. He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR et al. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-patient studies. Med Phys 2009;36:1595-1601
10. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996;41:1871-1884
11. Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005;20:47-51. (Pubitemid 40478521)
12. Baechlera S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys 2008;35:1123-1134 (Pubitemid 351322658)
13. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm 2004;19:363-370 (Pubitemid 38924502)
14. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response - implications for radionuclide therapy. J Nucl Med 2008;49:1884-1899.
15. Jones B, Dale RG. Mathematical Models of Tumour and Normal Tissue Response. Acta Oncologica 1999;38:883-893
16. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med 1999;40:1337-1341
17. Kalogianni E, Flux GD, Malaroda A. The Use of BED And EUD Concepts in Heterogeneous Radioactivity Distributions on a Multicellular Scale for Targeted Radionuclide Therapy. Cancer Biother Radiopharm 2007;22:143-150 (Pubitemid 46697377)
18. Mariani G, Bodei L, Adelstein SJ, Kassis AI. Emerging roles for radiometabolic therapy of tumors based on auger electron emission. J Nucl Med 2000;41:1519-1521
19. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999;10(Suppl 2):S23-9.
20. de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133-140 (Pubitemid 34311079)
21. Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP et al. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nucl Med Commun 2008;29:283-290
22. Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999;40:762-767
23. Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols L et al. Practical Dosimetry of Peptide Receptor Radionuclide Therapy with 90Y-Labeled Somatostatin Analogs. J Nucl Med 2005;46:92S-98S.
24. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282
25. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467-1475 (Pubitemid 47544933)
26. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-1626 (Pubitemid 47476920)
27. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751-1757
28. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72-79
29. Forster GJ, Engelbach MJ, Brockmann JJ, Reber HJ, Buchholz HG, Macke HR et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide. Eur J Nucl Med 2001;28:1743-1750 (Pubitemid 33141237)
30. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Cartier P et al. 86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect or different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510-518
31. Helisch A, Förster GJ, Reber H, Buchholz HG, Arnold R, Goke B et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1386-1392
32. Pentlow KS, Finn RD, Larson SM, Erdi YE, Beattie BJ, Humm JL. Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. Clin Positron Imaging 2000;3:85-90.
33. Walrand S, Jamar F, Mathieu I, De Camps J, Lonneux M, Sibomana M et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med Mol Imaging 2003;30:354-361 (Pubitemid 36692859)
34. Buchholz HG, Herzog H, Forster GJ, Reber H, Nickel O, Rosch F et al. PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction. Eur J Nucl Med Mol Imaging 2003;30:716-720
35. Fabbri C, Sarti G, Cremonesi M, Ferrari M, Di Dia A, Agostini M et al. Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. Cancer Biother Radiopharm 2009;24:145-154
36. Lhommel R, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Bilbao JI et al. Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging 2009;36:1696.
37. Minarik D, Sjögreen Gleisner K, Ljungberg M. Evaluation of quantitative (90)Y SPECT based on experimental phantom studies. Phys Med Biol 2008;53:5689-5703
38. Minarik D, Ljungberg M, Segars P, Gleisner KS. Evaluation of quantitative planar 90Y Bremsstrahlung whole-body imaging. Phys Med Biol 2009;54:5873-5883
39. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001;28:1319-1325
40. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF et al. Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. MIRD Pamphlet No.16. J Nucl Med 1999;40:S37-61.
41. van Rensburg, AJ, Lotter MG, Heyns AD, Minnaar PC. An evaluation of four methods of 111-In planar image quantification. Med Phys 1988;15:853-861
42. Minarik D, Sjögreen K, Ljungberg M. A new method to obtain transmission images for planar whole-body activity quantification. Cancer Biother Radiopharm 2005;20:72-76
43. Sjögreen K, Ljungberg M, Wingȧrdh K, Minarik D, Strand SE. The LundADose method for planar image activity quantification and absorbed-dose assessment in radionuclide therapy. Cancer Biother Radiopharm 2005;20:92-97
44. Foster D, Barret P. Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. Proceedings of the Sixth International Radiopharmaceutical. Dosimetry Symposium, Oak Ridge Institute for Science and Education; 1998.
45. Thomas SR, Stabin MG, Chen CT, Samaratunga RC. MIRD Pamphlet No.14 revised: A dynamic urinary bladder model for radiation dose calculations. J Nucl Med. 1999;40:102S-3S.
46. Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F et al. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)- octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. EurJ Nucl Med 1999;26:877-886
47. Forrer F, Uusijärvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J et al. A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1257-1262
48. Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2006;33:532-540
49. Hindorf C, Chittenden S, Causer L, Lewington VJ, Mäcke HR., Flux GD. Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm 2007;22:130-135
50. Cremonesi M, Ferrari M, Bodei L, Bartolomei M, Chinol M, Mei R et al. Dosimetry in patients undergoing 177Lu-DOTATATE therapy with indications for 90Y-DOTATATE. Eur J Nucl Med Mol Im 2006;33:S102.
51. Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate Eur J Nucl Med Mol Imaging 2009 [Epub ahead of print].
52. Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP. Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 2007;22:406-416
53. Walrand S, Barone R, Jamar F, De Camps J, Krenning EP, Valkema R et al. Red marrow 90YoctreoTher dosimetry estimated using 86Yoctreother PET and biological correlates. EJNM 2002;29:P434.
54. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-OTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2009;36:1138-1146
55. Forssell-Aronsson E, Fjalling M, Nilsson O, Tisell LE, Wangberg B, Ahlman H. Indium-111 activity concentration in tissue samples after intravenous injection of indium-11-DTPA-D-Phe-1-octreotide. JNM 1995;36:7-12.
56. Sgouros G. Dosimetry of internal emitters. J Nucl Med 2005;46:18S-27S.
57. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9-15.
58. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med 2003;30:207-216
59. Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2009 [Epub ahead of print].
60. Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA etal. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med 2003;44:1113-1147
61. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L et al. Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship. J Nucl Med 2005;46:99S-106S.
62. Konijnenberg MW, De Jong M, Valkema R, Krenning EP. Combined functional status and dose-volume analysis for determining renal damage threshold with radionuclide therapy. Eur J Nucl Med 2004;31:S239.
63. Green A, Flynn A, Pedley RB, Dearling J, Begent R. Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture. Cancer Biother Radiopharm 2004;19:371-377
64. de Jong M, Valkema R, Van Gameren A, Van Boven H, Bex A, Van De Weyer EP et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [111In-DTPA]octreotide. J Nucl Med 2004;45:1168-1171
65. Konijnenberg M, Melis M, Valkema R, Krenning E, de Jong M. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 2007;48:134-142
66. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-2762
67. International Commission on Radiological Protection. Recommendations of the international commission on radiological protection. ICRP Publication 60.
68. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-422
69. Cremonesi M, Bodei L, Botta F, Di Dia A, Ferrari M, De Cicco C et al. Time interval, number of cycles and radionuclide choice in PRRT (Peptide Receptor Radionuclide Therapy): radiobiological considerations to guide therapy planning. Eur J Nucl Med Mol Imaging 2009;36:S194-233.
70. Botta F, Valente M, Di Dia A, Cremonesi M, Ferrari M, Paganelli G et al. 3D absorbed dose distribution inside and outside 90Y, 177Lu and 131I sources of spherical shape by Monte Carlo simulation with the PENELOPE algorithm. Eur J Nucl Med Mol Imaging 2008;35:S201.
71. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 1994;35:152-156
72. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-Labeled somatostatin analogs. J Nucl Med 2005;46:13S-7S.
73. Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, Mikolajczak R, Sowa-Staszczak A, Pawlak D et al. Comparison between clinical results of PRRT with 90Y-DOTATATE and 90Y/177Lu-DOTA-TATE. Eur J Nucl Med Mol Imaging 2009;36:S194-233.
74. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH et al. Survival and Response After Peptide Receptor Radionuclide Therapy with [90Y-DOTA0,Tyr3]Octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Seminars in Nuclear Medicine 2006;36:147-156
75. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28:426-434
76. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P et al .Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439-1447
77. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002;43:610-616
78. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-2130
79. Bodei L, Cremonesi M, Grana C, Bartolomei M, Baio S, Bufi G et al. Receptor radionuclide theraphy with 177LU-DOTATATE in neuroendocrine tumours. Eur J Nucl Med Mol Im 2006;33:S214.
80. Bodei L, Cremonesi M, Grana C, Bartolomei M, Rocca P, Ferrari M, et al. Long-term evaluation of renal toxicity after receptor radionuclide theraphy with 90Y-DOTATOC and 177LU-DOTATATE. Eur J Nucl Med Mol Im 2006;33:S214.
81. Perez A, Brady LW. Principles and practice of radiation oncology. Philadelphia, PA: Lippincott-raven Publishers; 1997.
82. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122
83. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with (90)Y-DOTATOC and (177)Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847-1856.
84. Svensson J, Molne J, Schmitt A, Wikstrom A, Forssell-Aronsson, Bernhardt P. Equal mean absorbed kidney dose from 177Lu-DOTATATE will generate different kidney toxicity profiles in nude mice. Eur J Nucl Med Mol Imaging 2009;36:S206.
85. Pacilio M, Betti M, Cicone F, Del Mastro C, Montani L, Chiacchiararelli L et al. A theoretical dose-escalation study based on biological effective dose in the radioimmunotherapy with 90Y-Ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2010 [Epub ahead of print].
86. Antipas V, Dale RG, Coles IP. A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd. Phys Med Biol 2001;46:2557-2569
87. Uusijärvi H, Bernhardt P, Forssell-Aronsson E. Tumour control probability (TCP) for non-uniform activity distribution in radionuclide therapy. Phys Med Biol 2008;53:4369-4381